

SHREE GANESH BIO-TECH (INDIA) LIMITED

CIN:L70101WB1982PLC121196

Reg. Office: 6TH FLOOR, PREMISES 602, MAHAVIR APARTMENT 2, ASHUTOSH MUKHERJEE ROAD KOLKATA-700020

Email: shreeganeshbiotechindia ltd@gmail.com

Date: 04.08.2018

To,
Listing Department,
BSE Limited,
P J Tower, Dalal
Street
Mumbai-400001

To,
The Secretary,
The Calcutta Stock
Exchange Ltd,
7, Lyons Range,
Kolkata - 700001

To,
Head - Listing
Metropolitan Stock Exchange of
India Limited
Vibgyor Towers, 4th floor, Plot No
C 62, Opp. Trident Hotel Bandra
Kurla Complex, Bandra (E),
Mumbai - 400098

Scrip Code: 539470

Scrip Code: 29221

Scrip Code: SHREEGANES

Dear Sir/Madam,

Sub: Submission of Audited Financial Result for quarter ended 30th June, 2018 pursuant to Regulation 33 of the SEBI (LODR) Regulations, 2015

Further to our letter dated 24th July, 2018, we would like to inform that the Board of Directors of the Company at its meeting held on Saturday, 4th August 2018 has approved Un-audited Financial Results for the first quarter ended 30th June, 2018.

In terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith the following:

1. Un-audited Standalone Financial Results for the first quarter ended 30th June 2018.
2. Limited Review Report on the Standalone Financial Results

The Board meeting commenced at 17:00 Hrs and concluded at 18:15 Hrs We request you to take the same on records.

Thanking you.

Yours faithfully,

FOR, SHREE GANESH BIOTECH (INDIA) LTD

DIRECTOR / AUTHORIZED SIGNATORY



Shree Ganesh Biotech (India) Ltd

CIN:- L70101WB1982PLC121196

Regd. Office: 6th Floor, Premises - 602, Mahavir Apartment, 2, Ashutosh Mukherjee Road, Kolkata - 700020

Email:- shreeganeshbiotechindia@gmail.com

Statement of Unaudited Financial Results for the Quarter Ended June 30, 2018


Sl no.	Particulars	(Rs. In lacs)			
		Quarter Ended 30 June 2018	Quarter Ended 31st March 2018	Quarter Ended 30 June 2017	Year Ended 31 Mar 2018
	(Refer Notes Below)	(Unaudited)	(Audited)	(Unaudited)	(Audited)
1	INCOME				
(a)	Revenue from Operations	98.87	118.18	481.50	785.76
(b)	Other Income	-	-	-	-
	Total Income	98.87	118.18	481.50	785.76
2	EXPENSES				
(a)	Cost of material consumed	64.25	75.03	198.90	336.53
(b)	Purchase of stock in trade	-	-	-	-
(c)	Changes in inventories of finished goods, work-in-progress, and stock-in-trade	-	-	-	-
(d)	Employee benefit expense	1.20	7.36	1.05	9.66
(e)	Finance Costs	-	-	-	-
(f)	Depreciation and Amortization Expense	-	-	-	-
(g)	Other expenses	20.95	20.25	7.19	89.53
	Total Expenses	86.40	102.64	207.14	435.72
3	Profit for the Period before Share of Profit / (Loss) of Associates And Joint Ventures	12.47	15.54	274.36	350.04
4	Share of Profit/ (Loss) of Associates & Joint Venture	-	-	-	-
5	Profit before tax	12.47	15.54	274.36	350.04
6	Tax Expense	-	-	-	-
7	Net Profit after taxes and Share of Profit/ (Loss) of Associates and Joint Ventures but before non-controlling interests	12.47	15.54	274.36	350.04
8	Non-controlling interests	-	-	-	-
9	Net Profit after taxes, non-controlling interests and share of profit / (loss) of Associates and Joint Ventures	12.47	15.54	274.36	350.04
10	Other comprehensive income				
A.	(i) Items that will not be reclassified to profit or loss	-	-	-	-
	(ii) Income tax relating to items that will not be reclassified profit or	-	-	-	-
B.	(i) Items that will be reclassified to Profit or Loss	-	-	-	-
11	Total comprehensive income (9+10)	12.47	15.54	274.36	350.04
14	Paid-up equity share capital (Face Value of Rs.10/- each)	183.12	183.12	183.12	183.12
15	Other Equity				2,103.84
16	Earnings Per Share (of Rs. 10/- each) (not annualised):				
(a)	Basic	0.68	0.85	14.98	19.12
(b)	Diluted	0.68	0.85	14.98	19.12

Notes:

- 1 The above financial results have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on August 04, 2018. The Statutory Auditors have carried out a limited review of the above financial result.
- 2 Company has only one segment and hence no separate segment result has been given.
- 3 The figure of previous period/year have been re-grouped / re-arranged and /or recast wherever found necessary.
- 4 This statement is as per Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015

Place : Kolkata

Date : 4th August, 2018





To
The Board of Directors of
Shree Ganesh Biotech (India) Ltd

We have reviewed the accompanying Statement of Standalone Unaudited Financial Results of Shree Ganesh Biotech (India) Ltd ("the Company"), for the Quarter ended June 30, 2018 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016.

This Statement which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.


We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of Company personnel and an analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and, accordingly, we do not express an audit opinion.

Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the aforesaid Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: VADODARA
Date: 04.08.2018



For Bipin & Co.
Chartered Accountants
FRNo.: 101509W


(CA Amit Shah)
Partner
M. No.: 126337